Problems › Margins Are Shrinking › Healthcare Providers
Margin rarely falls because costs rose. It falls because mix changed and nobody repriced. This page works through it for healthcare providers specifically — including an unedited excerpt from a real analysis of a healthcare provider.
Margin rarely falls because costs rose. It falls because mix changed and nobody repriced. What makes this harder for healthcare providers is structural: downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Any credible answer therefore has to hold cost per episode and payer mix in the same view, which is exactly where most internal analysis stops because the two live in different systems.
A shrinking margin has three possible causes and they call for opposite responses. Input costs rose and price did not follow. Mix shifted toward the things you sell at a worse margin. Or cost to serve rose invisibly — more support, more customisation, more rework — inside customers whose price never changed.
The third is the most common and the hardest to see, because it never appears as a cost increase. It appears as the same revenue requiring more of the business to deliver it. Blended margin hides it completely: two customers at 45% and 15% average to a perfectly respectable 30%.
Which is why the first useful step is almost never a cost programme. It is disaggregating margin by product, by customer and by channel until the average stops lying to you.
These three together are the signature. One on its own usually points somewhere else.
✓ Revenue is up and profit is not
✓ Margin looks fine in aggregate and nobody can name the margin on a specific account
✓ Discounting has become routine at the close of a quarter
The move that usually makes it worse. Running an across-the-board cost reduction, which cuts hardest into the profitable half of the business because that is where the capacity sits.
It is for you if you run or finance a healthcare provider and revenue is up and profit is not. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Cost & Margin Improvement, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
Price, if the analysis shows your realised price has drifted below the value you deliver — it arrives on the next invoice and requires no new customers. Cost, if the problem is cost to serve rather than price. Doing both at once makes it impossible to tell which one worked.
You do not need one. Take the ten largest customers and allocate the obvious variable effort — support hours, delivery exceptions, custom work, payment terms. The ranking is almost always clear long before the numbers are precise, and the ranking is the decision.
No. Deliberately buying share with margin is a strategy. The problem is drifting into it without deciding to, which is what almost always happens, because each individual discount is defensible and the pattern is invisible until the year closes.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.